Chronic Lymphocytic Leukemia
Modified killer T-cells wipe out leukemia: study
Three US cancer patients were brought back from the brink by a new therapy that turned their own immune cells into tumor killers, wiping out an advanced form of leukemia, researchers said Wednesday.
Cancer
Aug 10, 2011 |
5 / 5 (18) |
3
T-cell therapy eradicates an aggressive leukemia in two children
Two children with an aggressive form of childhood leukemia had a complete remission of their disease-showing no evidence of cancer cells in their bodies-after treatment with a novel cell therapy that reprogrammed their immune ...
Cancer
Mar 25, 2013 |
5 / 5 (4) |
0
|
Monoclonal antibody targets, kills leukemia cells
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
Cancer
Mar 25, 2013 |
5 / 5 (4) |
0
|
Immune therapy shows early promise for advanced leukemia
(HealthDay)—An experimental therapy that targets the immune system might offer a new way to treat an often deadly form of adult leukemia, a preliminary study suggests.
Cancer
Mar 20, 2013 |
5 / 5 (3) |
0
|
Leap in leukemia treatment reported by Dartmouth researchers
Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively. The research was published online on May 3, 2013, ...
Cancer
May 13, 2013 |
5 / 5 (3) |
0
Molecule treats leukemia by preventing cancer cell repair, scientists report
(Medical Xpress)—Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment ...
Cancer
Apr 17, 2013 |
4.7 / 5 (3) |
0
|
B cell receptor inhibitor causes chronic lymphocytic leukemia remission
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting ...
Cancer
Dec 11, 2011 |
5 / 5 (2) |
0
Novel export-inhibitor shows promise for treating chronic lymphocytic leukemia
An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, ...
Cancer
Dec 12, 2011 |
5 / 5 (2) |
0
Massive DNA search uncovers new mutations driving blood cancer
The most comprehensive search to date of DNA abnormalities in chronic lymphocytic leukemia (CLL) has unearthed several new altered genes that drive this common blood cancer, a finding that could potentially ...
Cancer
Dec 12, 2011 |
5 / 5 (2) |
0
|
Leukemia patients remain in remission more than two years after engineered T cell therapy
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the ...
Cancer
Dec 10, 2012 |
5 / 5 (2) |
0
Drug combination acts against aggressive chronic lymphocytic leukemia
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of ...
Cancer
Dec 10, 2012 |
5 / 5 (2) |
0
Age no longer a barrier to stem cell transplantation for older patients
Age alone no longer should be considered a defining factor when determining whether an older patient with blood cancer is a candidate for stem cell transplantation. That's the conclusion of the first study summarizing long-term ...
Cancer
Nov 01, 2011 |
4.5 / 5 (2) |
0
|
Experimental drug combination selectively destroys lymphoma cells
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
Cancer
Feb 06, 2013 |
4.5 / 5 (2) |
0
|
UT MD Anderson Cancer Center launches unprecedented Moon Shots Program
The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical ...
Cancer
Sep 21, 2012 |
4 / 5 (2) |
1
Novel experimental agent is highly active in CLL patients, interim study shows
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Cancer
Dec 11, 2011 |
3.5 / 5 (2) |
0
B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia. Leukemias are cancers of the white blood cells (leukocytes). CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In CLL, the DNA of a B cell is damaged, so that it cannot produce antibodies.[citation needed] Additionally, B cells grow out of control and accumulate in the bone marrow and blood, where they crowd out healthy blood cells. CLL is a stage of small lymphocytic lymphoma (SLL), a type of B-cell lymphoma, which presents primarily in the lymph nodes. CLL and SLL are considered the same underlying disease, just with different appearances.
CLL is a disease of adults, but, in rare cases, it can occur in teenagers and occasionally in children (inherited). Most (>75%) people newly diagnosed with CLL are over the age of 50, and the majority are men.
Most people are diagnosed without symptoms as the result of a routine blood test that returns a high white blood cell count, but, as it advances, CLL results in swollen lymph nodes, spleen, and liver, and eventually anemia and infections. Early CLL is not treated, and late CLL is treated with chemotherapy and monoclonal antibodies.
DNA analysis has distinguished two major types of CLL, with different survival times. CLL that is positive for the marker ZAP-70 has an average survival of 5 years. CLL that is negative for ZAP-70 has an average survival of more than 25 years. Many patients, especially older ones, with slowly progressing disease can be reassured and may not need any treatment in their lifetimes.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Latest Spotlight News
Motion quotient: IQ predicted by ability to filter motion (w/ video)
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
Defective cellular waste removal explains why Gaucher patients often develop Parkinson's disease
Gaucher disease causes debilitating and sometimes fatal neurodegeneration in early childhood. Recent studies have uncovered a link between the mutations responsible for Gaucher disease and an increased risk ...
Protein preps cells to survive stress of cancer growth and chemotherapy
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
The secret lives, and deaths, of neurons
As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon—the "business end" of the neuron that sends electrical impulses to tissues or other ...
Regenerating spinal cord fibers may be treatment for stroke-related disabilities
A study by researchers at Henry Ford Hospital found "substantial evidence" that a regenerative process involving damaged nerve fibers in the spinal cord could hold the key to better functional recovery by most stroke victims.
Researchers suggest boosting body's natural flu killers
A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...
Pay attention: How we focus and concentrate
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
New discovery in fight against deadly meningococcal disease
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
Are kids who take music lessons different from other kids?
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
Study reveals active site of enzyme linked to stuttering
(Medical Xpress)—Scientists from the Joint Center for Structural Genomics (JCSG) at SLAC National Accelerator Laboratory have determined the 3-D structure of the chemically active part of an enzyme involved ...